Phase I/II clinical trial - Pédiatrie Tumeurs solides

INFORM2 - NIVENT (IC 2018-07)
Pédiatrie Tumeurs solides
Ouvert depuis le: 03.03.2024
Site: Paris
Public cible
INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies
Description de l'essai
The aim of this trial is to determine preliminary activity of the combination treatment with nivolumab and entinostat in children and adolescents with high risk refractory/relapsed/progressive tumors harboring a high mutational load, high PD-L1 mRNA expression or focal MYC(N) amplification and explore activity in biomarker low tumors (low mutational load, low PD-L1 mRNA expression and non-MYC(N) amplified).
Investigateur principal